Literature DB >> 25608561

Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Elizabeth C Schramm1, Lubka T Roumenina2, Tania Rybkine2, Sophie Chauvet2, Paula Vieira-Martins3, Christophe Hue2, Tara Maga4, Elisabetta Valoti5, Valerie Wilson6, Sakari Jokiranta7, Richard J H Smith4, Marina Noris5, Tim Goodship8, John P Atkinson1, Veronique Fremeaux-Bacchi9.   

Abstract

The pathogenesis of atypical hemolytic uremic syndrome (aHUS) is strongly linked to dysregulation of the alternative pathway of the complement system. Mutations in complement genes have been identified in about two-thirds of cases, with 5% to 15% being in C3. In this study, 23 aHUS-associated genetic changes in C3 were characterized relative to their interaction with the control proteins factor H (FH), membrane cofactor protein (MCP; CD46), and complement receptor 1 (CR1; CD35). In surface plasmon resonance experiments, 17 mutant recombinant proteins demonstrated a defect in binding to FH and/or MCP, whereas 2 demonstrated reduced binding to CR1. In the majority of cases, decreased binding affinity translated to a decrease in proteolytic inactivation (known as cofactor activity) of C3b via FH and MCP. These results were used to map the putative binding regions of C3b involved in the interaction with MCP and CR1 and interrogated relative to known FH binding sites. Seventy-six percent of patients with C3 mutations had low C3 levels that correlated with disease severity. This study expands our knowledge of the functional consequences of aHUS-associated C3 mutations relative to the interaction of C3 with complement regulatory proteins mediating cofactor activity.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25608561      PMCID: PMC4392009          DOI: 10.1182/blood-2014-10-609073

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  Structures of complement component C3 provide insights into the function and evolution of immunity.

Authors:  Bert J C Janssen; Eric G Huizinga; Hans C A Raaijmakers; Anja Roos; Mohamed R Daha; Kristina Nilsson-Ekdahl; Bo Nilsson; Piet Gros
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

Review 2.  Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.

Authors:  Anna Richards; M Kathryn Liszewski; David Kavanagh; Celia J Fang; Elizabeth Moulton; Veronique Fremeaux-Bacchi; Giuseppe Remuzzi; Marina Noris; Timothy H J Goodship; John P Atkinson
Journal:  Mol Immunol       Date:  2006-08-01       Impact factor: 4.407

3.  Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity.

Authors:  E M Adams; M C Brown; M Nunge; M Krych; J P Atkinson
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

4.  Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35).

Authors:  A E Oran; D E Isenman
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

5.  Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties.

Authors:  D E Isenman; D I Kells; N R Cooper; H J Müller-Eberhard; M K Pangburn
Journal:  Biochemistry       Date:  1981-07-21       Impact factor: 3.162

6.  Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

Authors:  Marie Frimat; Fanny Tabarin; Jordan D Dimitrov; Caroline Poitou; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Blood       Date:  2013-05-21       Impact factor: 22.113

7.  Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration.

Authors:  Yi Yu; Michael P Triebwasser; Edwin K S Wong; Elizabeth C Schramm; Brett Thomas; Robyn Reynolds; Elaine R Mardis; John P Atkinson; Mark Daly; Soumya Raychaudhuri; David Kavanagh; Johanna M Seddon
Journal:  Hum Mol Genet       Date:  2014-05-20       Impact factor: 6.150

8.  Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.

Authors:  Luca Ermini; Timothy H J Goodship; Lisa Strain; Michael E Weale; Steven H Sacks; Heather J Cordell; Veronique Fremeaux-Bacchi; Neil S Sheerin
Journal:  Mol Immunol       Date:  2011-12-05       Impact factor: 4.407

9.  Structural basis for engagement by complement factor H of C3b on a self surface.

Authors:  Hugh P Morgan; Christoph Q Schmidt; Mara Guariento; Bärbel S Blaum; Dominic Gillespie; Andrew P Herbert; David Kavanagh; Haydyn D T Mertens; Dmitri I Svergun; Conny M Johansson; Dušan Uhrín; Paul N Barlow; Jonathan P Hannan
Journal:  Nat Struct Mol Biol       Date:  2011-02-13       Impact factor: 15.369

10.  The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.

Authors:  Viviana P Ferreira; Andrew P Herbert; Claudio Cortés; Kristi A McKee; Bärbel S Blaum; Stefan T Esswein; Dusan Uhrín; Paul N Barlow; Michael K Pangburn; David Kavanagh
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

View more
  46 in total

Review 1.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

2.  aHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcome.

Authors:  Ekaterini Siomou; Athanasios Gkoutsias; Anastasios Serbis; Konstantinos Kollios; Nikolaos Chaliasos; Veronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-11-16       Impact factor: 3.714

3.  Complement activation: an atypical presentation of an atypical syndrome.

Authors:  Alfredo Iardino; Viviane Bunin; Luan D Truong; Hector Alejandro Preti
Journal:  BMJ Case Rep       Date:  2017-10-30

Review 4.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

5.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

6.  A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.

Authors:  Sophie Chauvet; Lubka T Roumenina; Sarah Bruneau; Maria Chiara Marinozzi; Tania Rybkine; Elizabeth C Schramm; Anuja Java; John P Atkinson; Jean Claude Aldigier; Frank Bridoux; Guy Touchard; Veronique Fremeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2015-10-15       Impact factor: 10.121

7.  Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.

Authors:  Maria Chiara Marinozzi; Lubka T Roumenina; Sophie Chauvet; Alexandre Hertig; Dominique Bertrand; Jérome Olagne; Marie Frimat; Tim Ulinski; Georges Deschênes; Stephane Burtey; Michel Delahousse; Bruno Moulin; Christophe Legendre; Véronique Frémeaux-Bacchi; Moglie Le Quintrec
Journal:  J Am Soc Nephrol       Date:  2017-01-17       Impact factor: 10.121

8.  Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Authors:  Fadi Fakhouri; Marc Fila; François Provôt; Yahsou Delmas; Christelle Barbet; Valérie Châtelet; Cédric Rafat; Mathilde Cailliez; Julien Hogan; Aude Servais; Alexandre Karras; Raifah Makdassi; Feriell Louillet; Jean-Philippe Coindre; Eric Rondeau; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-31       Impact factor: 8.237

Review 9.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

10.  Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.

Authors:  Vasil V Vasilev; Remi Noe; Marie-Agnes Dragon-Durey; Sophie Chauvet; Valentin J Lazarov; Boriana P Deliyska; Veronique Fremeaux-Bacchi; Jordan D Dimitrov; Lubka T Roumenina
Journal:  J Biol Chem       Date:  2015-08-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.